Review article · 2026 · Open access

Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer

Akshara Singareeka Raghavendra, Senthil Damodaran, Carlos Hernando Barcenas, Suzanne A.W. Fuqua, Rachel M. Layman, Debu Tripathy

CA A Cancer Journal for Clinicians, 76(1), e70055 · Published 1 January 2026 · DOI 10.3322/caac.70055

Open PDFView at the publisherCite this paper

In brief

“Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer” is a 2026 review article by Akshara Singareeka Raghavendra and 5 co-authors, published in CA A Cancer Journal for Clinicians. OpenAlex counts 23 citations as of 17 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at CA A Cancer Journal for Clinicians.

Citations
23
Most cited in
2026 (23)
Field-weighted impact
12.68
References
190
Authors
6

Abstract

The hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer subtype accounts for most early and metastatic breast cancer (MBC) cases. HR-positive/HER2-negative MBC is characterized by a relatively prolonged, although variable, disease course and substantial intertumoral and intratumoral heterogeneity. Although endocrine-based therapies remain the cornerstone of treatment, nearly all patients eventually develop resistance, which is increasingly addressed with biologically targeted agents and newer-generation cytotoxic drugs. This review summarizes the current understanding of HR-positive/HER2-negative MBC biology, highlighting mechanisms of intrinsic and acquired resistance, including driver genomic alterations that, along with clinical factors, help guide therapeutic choices and sequencing. The authors specify and discuss how genomic and transcriptomic profiling inform treatment selection and how side effects and overall patient experience are considered in decision making. Advances in targeted therapies, such as CDK4/6 (cyclin-dependent kinase 4/6), PI3K (phosphatidylinositol 3-kinase), and AKT (protein kinase B) inhibitors, and next-generation estrogen receptor degraders are reviewed along with the expanding role of antibody-drug conjugates and biomarker-guided tumor-agnostic biologic therapies. The authors also explore evolving biologic concepts, including the impact of the tumor microenvironment on resistance and disease progression, and consider the distinct clinical behavior of invasive lobular carcinoma and current approaches. Emerging data from contemporary clinical trials promise to refine clinical and biomarker-driven algorithms and improve outcomes for patients with HR-positive/HER2-negative MBC. Ongoing multi-omic research and adaptive clinical strategies will be essential to further the application of precision oncology in this most common subtype of MBC. Importantly, patient-reported outcomes, shared decision making, and real-world evidence are increasingly useful in formulating comprehensive care plans, guidelines, and policy. The modern treatment landscape features a personalized approach that integrates clinical features, biomarkers, and patient preferences across the disease continuum.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Raghavendra, A. S., Damodaran, S., Barcenas, C. H., Fuqua, S. A., Layman, R. M., & Tripathy, D. (2026). Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer. CA A Cancer Journal for Clinicians, 76(1), e70055. https://doi.org/10.3322/caac.70055

MLA 9

Raghavendra, Akshara Singareeka, et al. “Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer.” CA A Cancer Journal for Clinicians, vol. 76, no. 1, 2026, p. e70055. https://doi.org/10.3322/caac.70055.

Chicago

Raghavendra, Akshara Singareeka, Senthil Damodaran, Carlos Hernando Barcenas, Suzanne A.W. Fuqua, Rachel M. Layman, and Debu Tripathy. 2026. “Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer.” CA A Cancer Journal for Clinicians 76 (1): e70055. https://doi.org/10.3322/caac.70055.

Harvard

Raghavendra, A. S. et al. (2026) ‘Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer’, CA A Cancer Journal for Clinicians, 76(1), p. e70055. doi:10.3322/caac.70055.

IEEE

A. S. Raghavendra, S. Damodaran, C. H. Barcenas, S. A. Fuqua, R. M. Layman, and D. Tripathy, “Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer,” CA A Cancer Journal for Clinicians, vol. 76, no. 1, p. e70055, 2026, doi: 10.3322/caac.70055.

BibTeX

@article{raghavendra2026personalizing,
  title     = {{Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer}},
  author    = {Raghavendra, Akshara Singareeka and Damodaran, Senthil and Barcenas, Carlos Hernando and Fuqua, Suzanne A.W. and Layman, Rachel M. and Tripathy, Debu},
  journal   = {CA A Cancer Journal for Clinicians},
  year      = {2026},
  volume    = {76},
  number    = {1},
  pages     = {e70055},
  doi       = {10.3322/caac.70055},
  url       = {https://doi.org/10.3322/caac.70055}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies

  • hormone receptor-positive HER2-negative breast cancer
  • metastatic breast cancer
  • endocrine therapy resistance
  • CDK4/6 inhibitors
  • PI3K/AKT inhibitors
  • antibody-drug conjugates
  • tumor-agnostic therapy
  • tumor microenvironment

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Raghavendra, A. S., Damodaran, S., Barcenas, C. H., Fuqua, S. A., Layman, R. M., & Tripathy, D. (2026). Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer. CA A Cancer Journal for Clinicians, 76(1), e70055. https://doi.org/10.3322/caac.70055

How many times has this paper been cited?

23 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at CA A Cancer Journal for Clinicians: sign in and open the PDF from this page.

Who wrote this paper?

Akshara Singareeka Raghavendra, Senthil Damodaran, Carlos Hernando Barcenas, Suzanne A.W. Fuqua, Rachel M. Layman, Debu Tripathy.

What is the DOI of this paper?

10.3322/caac.70055, permanently at https://doi.org/10.3322/caac.70055. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.